Abstract
Global investments in cellular immunotherapies reflect their curative potential. Our landscape of clinical trials will aid developers, investors, adopters and payers in planning for adoption and implementation along realistic time horizons. Trend data enable stakeholders to adapt their business models and capacity to bring immunotherapies to the clinic. For cancer, trends suggest a shift from cancer vaccines to adoptive cellular transfer, alongside a focus on solid tumors. Academic centers, mainly in the USA, lead in early-phase clinical trials and target identification; but industry involvement has increased fourfold over the past two decades. Trends indicate an increasingly personalized approach to onco-immunology, which raises challenges for cost-effective manufacturing and delivery models. Overcoming these challenges provides opportunities for innovative biotechnology firms.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 623-636 |
| Number of pages | 14 |
| Journal | Regenerative Medicine |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sept 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adoptive cellular therapy
- cell therapy
- cellular immunotherapy
- clinical trial
- industry
- translational research
Fingerprint
Dive into the research topics of 'Opportunities and challenges for the cellular immunotherapy sector: A global landscape of clinical trials'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver